Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057445 · ClinicalTrials.gov registry record · Phase 1
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
A Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02057445 is a Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 1 participants.
The verdict
NCT02057445, a Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to be done), safe and well tolerated (no unexpected serious events will occur). In addition, potential donors who are EBV positive will be enrolled to donate peripheral blood to help build a bank of these specific EBV fighting cell lines.
Interventions
- DRUG EBV CTL's
- OTHER Peripheral Blood Donor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057445
The ClinicalTrials.gov registry entry for NCT02057445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EBV CTL's is the first listed.
NCT02057445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057445 about?
NCT02057445 is a clinical study titled "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma". The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to b...
What is the current status of trial NCT02057445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02057445?
The interventions under investigation include: EBV CTL's (DRUG), Peripheral Blood Donor (OTHER).
Who is sponsoring clinical trial NCT02057445?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.